The S&P/ASX 200 Index (ASX: XJO) was rangebound today and closed the session 0.11% in the green at 7,407.5 points.

Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) matched the broader market and also finished 0.11% higher today.

These 3 ASX health care shares stood out as clear winners amongst the packs, with each beating the market by 10% today. Here are the details.

Emyria Ltd (ASX: EMD)

Clinic and software operator Emyria came out 10% on top today despite there being no market sensitive information from the company.

However, Emyria shares took off in an almost vertical fashion last week and haven’t slowed since. The company did release a flurry of announcements this week. Even still, investors were piling in and driving up prices in the days beforehand.

For instance, it announced a collaboration with strategic investor Tattarang, where the private investment group secured $5 million in Emyria via a share placement.

The funds will be used to accelerate synthetic cannabinoid registration programs with the TGA and FDA, and advance Emyria’s novel MDMA-analogue development program with the University of Western Australia.

Then it followed up two days later advising it had received a $1.162 million R&D tax incentive refund, which kept its share price tracking upwards until today.

All in all, it’s been a pleasant gain this month for Emyria shareholders. After a slight hiccup mid-month, the Emyria share price has gained over 92% so far in November.

Control Bionics Ltd (ASX: CBL)

Shares in Control Bionics also came out on top today, closing around 11.5% higher at 45.75 cents. Control’s share price has been rolling downhill these past 3 months and has come off a 3-month low of 40.5 cents as of yesterday.

However, its presentation at the Morgans Investment conference yesterday appears to have gained investors’ attraction once more. In the display, the company noted that it is aiming to combine its “NeuroNode wearable technology with high quality eye-gaze camera technology creating market leading products that delivered faster communication speed and significantly less fatigue than existing competition globally”.

It also noted revenue of almost $4 million in FY21 and a healthy balance sheet with $12 million in liquidity as of 30 June 2021.

Control Bionics also intends to expand its product range within the assistive technology market for autism. Today’s gains are welcomed after a difficult year for the company’s share price, having posted a loss of 61% in the past 12 months.

Singular Health Group Ltd (ASX: SHG)

Shares in technology-driven imaging player Singular Health jumped 10% to finish at 27.5 cents. In fact, Singular Health shares have climbed 17% in the past 2 days, after hitting the ceiling at 30 cents last week.

Investors appear to have had a mixed reaction to confirmation that Singular is forming a 50/50 joint venture (JV) with TerraCentric Pty Ltd under the name of GeoVR Pty Ltd.

The sole purpose of the JV is to commercialise 3D and virtual reality software GeoVR technology. Specifically, the new company will focus on mineral exploration data to be visualised in a fully interactive 3D environment.

The move was labelled as a critical step by the company in diversifying away from traditional medical markets.

Following the release, shares jumped slightly, before tumbling over 21% in a matter of days. So today’s gains are a hard one to pinpoint but are definitely part of the wider volatility in this name.

For instance, the Singular Health share price has traded as high as 30 cents and closed as low as 16 cents in the past 3 months – a 130% spread in pricing.

These 3 ASX health care shares all cruised past the market today amid strengths in the wider sector.

The post 3 ASX health care shares that burned the market today appeared first on The Motley Fool Australia.

More reading

• Here’s why the Emyria (ASX:EMD) share price is up 17% to a record high
• These 3 ASX healthcare shares are soaring today. Why?

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3nOKkSo

Far from the grizzly rain that Guns and Roses associated with November, it’s been a decisively sunny month so far for the Lynas Rare Earths Ltd (ASX: LYC) share price. Today alone, Lynas managed to put on a healthy 0.92% to finish the trading day at $8.75 a share.

But today also saw Lynas hit a new 52-week high of $8.80 as well. Normally, a new 52-week high (or in this case, a 9-year high) would be a cause of celebration for shareholders.

But considering this is the ninth straight new high Lynas has made over November thus far, shareholders might have not even noticed yet. Or maybe the party just hasn’t stopped, considering the Lynas share price is now up close to 110% in 2021 so far.

So why has Lynas had such a stupendously successful eleventh month of the year?

Well, we can likely put it down to a few factors.

What’s behind the Lynas share price’s November sun?

The most pressing of these could be the announcement the company released at the start of the month. On 1 November, Lynas announced it had inked a letter of agreement with Japan Australia Rare Earths (JARE). This agreement reconfirmed JARE’s long-term support for Lynas and its operations.

As my Fool colleague Tristan reported at the time, JARE, along with Lynas, are both “parties to a long-term senior loan facility, with a principal balance of US$145 million, an interest rate of 2.5% per annum, and a maturity date of 30 June 2030”.

JARE’s ongoing support is likely a positive development for Lynas going forward. Particularly factoring in this line of credit. JARE has already agreed to defer more than one interest payment for Lynas, so investors may have been buoyed by this as well.

Further, Lynas delivered its quarterly activities report back in late October. When it did, it also informed investors that demand for its products was already very high. But Lynas is expecting even higher demand going into 2022.

Apart from these potential factors, it’s not entirely clear why Lynas has had such a strong November so far. It’s also worth pointing out that ASX lithium, battery, rare earths, and renewable energy shares have all enjoyed enormous interest from ASX investors in 2021. It’s very possible that Lynas’ success over November has been driven by this alone.

Whatever the reason, it’s just another top-notch month (so far) that Lynas shareholders can add to their bedposts.

At the last Lynas share price of $8.75, this ASX rare earths company has a market capitalisation of $7.9 billion. It also has a price-to-earnings (P/E) ratio of 48.6.

The post The Lynas (ASX:LYC) share price has hit 10 9-year highs so far this month. Here’s why appeared first on The Motley Fool Australia.

More reading

• Looking to invest in the electrification and battery theme? Here are 5 ASX shares to consider
• These were the best performing ASX 200 shares last week
• Why has the Lynas (ASX:LYC) share price just hit a 9-year high?
• The materials sector is leading the ASX 200 today. What’s going on with the Lynas (ASX:LYC) share price?
• What’s with the Lynas (ASX:LYC) share price today – up 8%?

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3DTvuPY

At the small end of the Australian share market, there are a number of companies with the potential to grow materially in the future.

Two that investors may want to get better acquainted with are listed below. Here’s what you need to know about them:

Alcidion Group Ltd (ASX: ALC)

The first small cap ASX share to watch is this Alcidion. It is a healthcare informatics solutions company behind innovative healthcare software products including Miya, Patientrack and Smartpage.

Miya combines artificial intelligence-based predictive analytics, clinical decision support (CDS), and mobile alerts in an easy-to-use analytics dashboard. This allows doctors to map the patient journey and view critical patient insights in real-time.

Patientrack uses predictive algorithms to support time-critical care and help clinicians know every patient’s status in real-time. This means doctors can intervene and prevent patient deterioration faster than ever before. Patientrack uses predictive algorithms to support time-critical care.

Finally, Smartpage is a quick messaging and task management platform. It delivers the simplicity of favourite messaging services with the security of encryption. It enables hospital staff to communicate and collaborate instantly.

The team at Bell Potter is positive on Alcidion’s future. In light of this, it currently has a buy rating and 45 cents price target on the company’s shares.

BlueBet Holdings Ltd (ASX: BBT)

Another small cap ASX share to watch is BlueBet. It is a mobile-first, online bookmaker aiming to provide more innovative wagering products to customers of Australian and international racing and sports.

BlueBet currently offers wagering products on 31 sports in Australia and internationally, plus entertainment and politics wagering markets. These include traditional wagering products as well as more innovative products, such as Exotics, Same Game Multis and Same Race Multis.

BlueBet has been growing very strongly over the last couple of years. This has been driven by the increasing popularity of mobile sports betting and strong customer growth. The good news is that management is confident that this trend can continue. It also believes it is well positioned to substantially grow its current share of the market in Australia, and has its eyes on the enormous US market.

Morgans is a fan of BlueBet. It currently has an add rating and $2.57 price target on the company’s shares.

The post 2 growing small cap ASX shares to watch appeared first on The Motley Fool Australia.

More reading

• 3 exciting small cap ASX shares to watch
• Brokers name 3 ASX shares to buy today
• Why Aussie Broadband, BlueBet, Hipages, and JB Hi-Fi shares are rising
• BlueBet (ASX:BBT) share price jumps 8% on record first quarter
• Alcidion (ASX:ALC) share price dips 4% despite positive quarterly update

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Alcidion Group Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd and BlueBet Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/30T6Il5

The S&P/ASX 200 Index (ASX: XJO) giant was hit hard by the onset of the COVID-19 pandemic. But now Australia is getting closer to normality once more, are Cochlear Limited (ASX: COH) shares worth buying?

Tribecca Investment Partners portfolio manager Jun Bei Liu thinks so.

The fundie believes the company is set to be a market beater, outperforming its competition and ASX 200 peers over the long term.

As of Thursday’s close, the Cochlear share price is $229.14. That’s 0.26% higher than it was at the end of Wednesday’s session.

Let’s look at why this professional recommends Cochlear shares.

Are Cochlear shares worth buying?

Like many ASX shares, Cochlear’s stock was hit hard by COVID-19.

Cochlear ultimately withdrew its guidance for financial year 2020 as the pandemic impacted its business. It later launched an $800 million capital raise to cover the resulting drop in income.

Come the end of financial year 2020, the company recorded an 11% drop in revenue on a constant currency basis, mainly due to restrictions on surgeries.

But looking beyond the pandemic, is Cochlear a buy?

Cochlear is a global leader in implantable hearing devices, and that’s exactly why Liu believes it’s one to buy now and hold for the future.

It currently holds more than 60% of the hearing device market, according to Liu. Additionally, she expects that market to grow as the global population ages.  

Liu told LiveWire another reason she thinks Cochlear shares are a buy is because the company works in an under-penetrated market – only 60,000 people receive implantable hearing devices each year.

That leaves the company with a strong growth pathway for the next 10 years.

Additionally, there are few technological advances that could see its products deemed obsolete. In fact, Cochlear is mostly only at risk of itself. Livewire quoted Liu as saying:

Cochlear is the most advanced with a fully implantable device which is likely to be the next major development in the space.

Finally, Liu likes Cochlear for its management team. She believes they are capable and focused on driving the company’s value higher over time.

However, its current value is a slight downside. Liu reportedly said:

As a high-quality business with defensive structural growth characteristics, the stock is trading at a meaningful premium to the rest of the ASX companies. Taking a longer-term view, however, Cochlear is absolutely a bottom drawer stock that will deliver growth year in and year out.

The post With restrictions easing, is the Cochlear (ASX:COH) share price a buy? appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 shares with major competitive advantages
• Macquarie warns the next ASX market downturn could come as soon as February
• Is the Cochlear (ASX:COH) share price heading back under $200?

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3r9qvYc

The MyDeal.Com Au Ltd (ASX: MYD) share price has been gradually recovering since May. A continuation in revenue growth has put the online retail marketplace in a good light. While the company is operating in a space filled with formidable foes, some investors are taking a liking to the smaller competitor.

Sydney-based private investment company EGP Capital is one such investor that is bullish on the MyDeal share price. The reasoning behind EGP Capital’s positive outlook for the company was shared in the fund’s October report.

Let’s jump into the details.

What makes the MyDeal share price worth looking at?

The team behind EGP Capital’s Concentrated Value fund are big backers of numerous ASX-listed retail-focused businesses. For example, Cettire Ltd (ASX: CTT), Redbubble Ltd (ASX: RBL), and MyDeal all make an appearance in the fund’s top 10 holdings.

According to the fund’s October report, rather than backing the larger online retailers, EGP is keener on the prospects ahead for MyDeal — with a market capitalisation of ~$225 million.

Chief investment officer (CIO) Tony Hansen detailed several reasons why the fast-growing retailer play is attractive. The first reason is the incentive structure in place for the MyDeal CEO and founder, Sean Senvirtne. Nearly half of the company’s shares are owned by Senvirtne.

However, the primary reason for EGP Capital’s interest in the MyDeal share price is the marketplace element. This involves connecting buyers with sellers through the company’s online platform, taking a fee from the transaction in the process.

Hansen notes that the cash flow generated by this business segment alone allows the business to grow without the need for external capital.

How does it compare to another online retailer?

Because of its capital-light nature, the fund prefers to compare MyDeal to Temple & Webster Group Ltd (ASX: TPW). In comparing the two, Hansen and the team believe that the smaller online retailer could be worth ~$1.40 if it were valued similarly to Temple and Webster.

Hansen came to this conclusion by comparing the companies enterprise value over gross margin (EV/GM). For Temple and Webster, this equates to ~7 times. Meanwhile, MyDeal’s EV/GM comes out to around 3 times.

Finally, EGP Capital suggests that if MyDeal can demonstrate revenue growth and profitability over several quarters, then it might attract a more premium valuation. For investors, this would translate to a higher MyDeal share price.

MyDeal shares are down 32% since the beginning of the year. Coming off of a booming time for online retailers during COVID-19, the company has failed to maintain the momentum.

The post This fund manager thinks the MyDeal (ASX:MYD) share price is appealing appeared first on The Motley Fool Australia.

More reading

• 3 exciting small cap ASX shares for your watchlist

Motley Fool contributor Mitchell Lawler owns shares of Kogan.com Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Cettire Limited and Temple & Webster Group Ltd. The Motley Fool Australia has recommended Cettire Limited and Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3p5cKam

The AMP Ltd (ASX: AMP) share price has failed to outperform the market this year, continuing its gradual decline. Despite delivering a largely sound third-quarter trading update last month, the financial services company is struggling with positive investor sentiment.

At the closing bell on Thursday, AMP shares finished down 5% at $1.05. This means its shares have lost nearly 10% in the past week.

What’s happened to AMP recently?

Investors have been dragging down the AMP share price despite a robust third-quarter update from the company on 21 October.

AMP reported that its capital assets under management (AUM) fell to $180.3 billion, a drop of 4.04% compared to the first half. The impact was primarily caused by net cash outflows which came to $12 billion for the quarter. In context, net cash outflows totalled $2.4 billion in Q3 FY20.

In AMP’s New Zealand wealth management portfolio, AUM increased to $12.9 billion, up $300 million quarter-on-quarter. The sound result was driven by investment market gains which offset net cash outflows of $39 million.

The demerger program is scheduled for competition by the middle of FY22. This will see the transition of MAG from AMP Capital to AMP Australia, creating a superannuation and investment platform business.

AMP advised it will provide a further update on its progress regarding the demerger at an Investor Day on 30 November. In addition, the company will also lay out what’s ahead for the remaining financial year as well as FY22.

How does the AMP share price compare to the financial sector?

Over the last 12 months, the AMP share price has moved 40% lower and is down by 33% year to date. The company’s shares hit a multi-decade low of 88.5 cents in September 2021, before moving in circles.

In contrast, the S&P/ASX 200 Financials Index (ASX: XFJ) has gained 14% from this time last year and is up almost 19% year to date. The sector also registered a 52-week high of 6,956.4 points in late October.

Undoubtedly, AMP shares are lagging behind the Financial Index which has continued to accelerate since March 2020.

Based on today’s price, AMP commands a market capitalisation of roughly $3.59 billion, with approximately 3.27 billion shares on issue.

The post How is the AMP (ASX:AMP) share price performing against the financial sector in 2021? appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are topping the volume charts on Monday
• ASX 200 (ASX:XJO) midday update: Lithium miners jump, Flight Centre tumbles
• AMP (ASX:AMP) share price lifts as company retains control of office fund
• Is there still hope for the AMP (ASX:AMP) share price?
• AMP (ASX:AMP) share price higher after $40 million APRA enforcement

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3nPpAd9

As a major big four ASX bank share (or big 5 these days), the Australia and New Zealand Banking Group Ltd (ASX: ANZ) share price has always been one of the most watched metrics on the S&P/ASX 200 Index (ASX: XJO). As a top 10 ASX 200 share, ANZ shares have a fairly large influence over the entire ASX 200.

So let’s take a journey through ANZ’s share price history. It’s quite telling to look at a blue chip share like ANZ through this lens, as we can really see how much it lives up to this reputation as a strong, stable and relatively safe investment.

So here’s how the ANZ share price looks over the past 10 years:

So as you can see, it’s far from ‘up and to the right’ for ANZ shares. At the last ANZ share price of $27.27, investors would have bought those same shares for that same price way back in February 2013. Or back in October 2006 for that matter. That’s 15 years of doing a whole lot of not much.

ANZ share price: stuck in the mud?

Of course, there was ANZ’s meaty and (mostly) fully franked dividends that would have helped ease the pain. But it’s safe to say that ANZ has not been a market-beating investment for most long-term shareholders over the past 15 years.

Of course, we’ve seen highs and lows far over and under that price over this period too. ANZ’s last all-time high was hit back in April 2015. Believe it or not, that’s when ANZ shares got close to $37 each. As it stands today (6½ years later), ANZ remains around 25% off of those highs. Just over the past 5 years alone, the ANZ share price remains down by 4.18%.

But then again, ANZ is also today a good 80% or so above the lows that we saw during the COVID crash last year. That was when ANZ got to under $15 a share. So it hasn’t been all bad news for shareholders. In more recent times, the picture has been a lot brighter too. ANZ is up 18.4% year to date in 2021 alone, and is also up 17.3% over the past 12 months.
Sometimes, perspective is everything!

At the current ANZ share price of $27.27, this ASX banking share has a market capitalisation of $76.88 billion, with a dividend yield of 5.21%.

The post ANZ (ASX:ANZ) share price history: What caused the biggest ups and downs? appeared first on The Motley Fool Australia.

More reading

• Own ANZ (ASX:ANZ) shares? Here’s how the bank just got booted out of the big four
• Macquarie (ASX:MQG) is now a big four bank
• Is the CBA (ASX:CBA) share price premium relative to other big banks justified?
• 2 ASX dividend shares with attractive yields to buy
• Leading brokers name 3 ASX shares to buy today

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3CPPCRK

The Fortescue Metals Group Limited (ASX: FMG) share price has been one to watch in 2021 so far.

It first got chins a-wagging when Fortescue hit a new all-time high of $26.58 a share back in July. That represented a gain of close to 40% just between late March and that date. This was of course fuelled by record-high iron ore prices, which climaxed at more than US$220 a tonne mid-year.

But in more recent months, the story has turned fairly nasty. Iron ore was not destined to remain at those highs for long. As of today, it is sitting at just over US4100 a tonne after falling close to US$90 recently. This naturally sent the Fortescue share price plummeting. It fell from over $26 a share in July to a new 52-week low of $13.90 by late October

It’s worth noting the Fortescue share price has recovered somewhat since then. It’s today sitting at $17.88, nearly 30% above its new low. Perhaps the hullabaloo surrounding Fortescue Future Industries has helped in this matter.

But at this current share price, Fortescue shares now offer a seemingly impossible dividend yield of 20.02%. Get ready for this — grossed-up with Fortescue’s full franking, that dividend yield is worth an insane 28.6%.

Can that be true? Are Fortescue shares really offering a yield of that stupendous magnitude right now?

Does Fortescue really have a 28% dividend on the table?

Well, not quite. A trailing dividend yield indicates the yield that investors would have received at the current Fortescue share price over the last 12 months. It doesn’t mean this will stay the same for the next 12 months.

So yes, Fortescue’s last two (fully franked) dividend payments came in at $2.11 per share and $1.47 per share respectively. That totals $3.58 a share in total and comes to a yield of 20.02% on the current Fortescue share price. But remember, these dividends were funded by the record-high iron ore prices we’ve just discussed. The market knows that with iron ore now less than half of the price it was just a few months ago, these dividends are not likely to be repeated next year. 

It might not be as bad as you might think though. As my Fool colleague Tristan covered earlier this week, brokers at Macquarie Group Ltd (ASX: MQG) are predicting Fortescue will still be able to pay out $1.97 in dividends per share for FY 2022, and $1.42 per share in FY 2023. That would still equate to sizeable raw yields of 11.02% and 7.94% respectively on the current Fortescue share price.

There will be more than a few shareholders who would be hoping that indeed turns out to be the case.

At the current Fortescue share price of $17.88, this miner has a market capitalisation of $55.42 billion.

The post Is the Fortescue (ASX:FMG) dividend really worth 28% in November? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX shares today
• Here are the 3 heaviest traded ASX 200 shares this Tuesday so far
• What’s causing the Fortescue (ASX:FMG) share price to leap 9% today?
• 2 high-yielding ASX 200 dividend shares
• Leading brokers name 3 ASX shares to sell today

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3HR7C1Q

The Endeavour Group Ltd (ASX: EDV) share price has risen by around 10% over the last four months. But is the company about to lose some of its fizz?

If readers haven’t heard of Endeavour before, it’s a business that was divested out of Woolworths Group Ltd (ASX: WOW).

The company owns several brands of alcohol and drinks businesses including Dan Murphy’s, BWS, Jimmy Brings, Cellarmasters, Langton’s, Pinnacle Drinks and Shorty’s Liquor.

Endeavour Group also has a hotels business, it’s the largest on-premise venue operator and currently manages a portfolio of more than 330 distinct licensed venues in capital cities and urban and regional centres.

Analysts aren’t bullish about the Endeavour share price

Whilst the business has been gaining in recent times, some analysts think the company has run too far.

Credit Suisse currently has a sell/underperform rating on the business with a price target of $6.19 – that’s more than 10% lower than where it is now.

The broker thinks that Endeavour is going to see growth of alcohol sales and a recovery for hotel revenue.

Credit Suisse thinks that Endeavour Group’s expenses will continue to be higher than normal.

Another broker – Morgans – thinks Endeavour is a hold with a price target of $6.95. Morgans also referenced the FY22 first quarter numbers to come to its opinion about the business which also includes expectations of a stronger performance from its hotel business and lockdowns seemingly much less likely to happen.

FY22 first quarter update

Let’s look at the first quarter numbers that the brokers are referring to. For the 14 weeks from 28 June 2021 to 3 October 2021, total sales fell by 1.2% to $2.94 billion.

There was a mixed performance between its two divisions. The retail sales were flat, falling by just 0.2% to $2.65 billion. But the hotels division, suffering from lockdowns in major markets, saw sales drop by 9.9% to $282 million. Nationally, around 40% of hotels were closed across the quarter and various trading restrictions were in place across the country.

Sales declines can obviously impact an investor’s thoughts about the Endeavour share price.

Of particular note, the online sales of the retail segment saw growth of 34.4% year on year. This saw the online penetration increased from 8.6% in FY21 to 11.5% in FY22. Endeavour acknowledged that a portion of this growth is due to the shift to at-home consumption because of venue closures. But the online penetration also grew outside of NSW and Victoria.

With the hotels business, Endeavour is thinking about the longer-term by investing in building and improving its hotels business. In the quarter, it acquired the Terrey Hills Tavern in NSW and The Manly Hotel in Queensland. It also carried out a renewal of the Sunnybank Hotel and has continued to implement digital ordering and payment technology across its hotels.

At the end of the quarter, its portfolio consisted of 336 hotels and five managed clubs.

The company said with its quarterly update:

Looking beyond the immediate challenges, the group is well positioned for growth, with a diversified portfolio of quality hotels, strong retail brands and digital assets, supported by a focused and resilient team.

Endeavour share price valuation

Using Credit Suisse’s estimate for FY22, Endeavour shares are valued at 28x FY22’s estimated earnings and 24x FY23’s estimated earnings.

The post Is the party over for the Endeavour (ASX:EDV) share price? appeared first on The Motley Fool Australia.

More reading

• The Woolworths (ASX:WOW) share price is up 20% so far in 2021. Here’s why
• Alcohol and intelligence: 2 ASX shares on the way up

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/2ZjI6AW

Today, the S&P/ASX 200 Index (ASX: XJO) pulled ahead in late trade to finish above its previous close. At the end of the session, the benchmark index finished 0.11% higher at 7,407.3 points.

The Aussie market fended off a negative performance today with the help of a stellar performance from tech shares. It appears investors had an appetite for tech companies, while banks and consumer staples fell to the wayside. To the benefit of the index, a number of miners decided to rally as iron ore reclaimed the US$100 per tonne threshold.

The question is: which shares delivered the biggest returns to investors on the ASX today? Here are the ten stocks that rose to the occasion:

Top 10 ASX shares countdown today

Looking at the top 200 listed companies, Novonix Ltd (ASX: NVX) was the biggest gainer today. Shares in the battery technology company jumped 11.68% higher. While the company had no new announcements today, it did reveal the opening of its new facility in Chattanooga, Tennessee yesterday. Find out more about Novonix here.

The next biggest gaining ASX share today was Nickel Mines Ltd (ASX: NIC). The nickel mining company rallied 6.46% to $1.40 despite there being no announcements from the company today. Uncover the latest Nickel Mines details here.

Today’s top 10 biggest gains were made in these ASX shares:

ASX-listed company	Share price	Price change
Novonix Ltd (ASX: NVX)	$10.71	11.68%
Nickel Mines Ltd (ASX: NIC)	$1.40	6.46%
Yancoal Australia Ltd (ASX: YAL)	$2.81	5.24%
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)	$32.29	4.57%
Technology One Ltd (ASX: TNE)	$11.99	4.53%
Mineral Resources Ltd (ASX: MIN)	$45.77	4.47%
Afterpay Ltd (ASX: APT)	$111.55	4.01%
Liontown Resources Ltd (ASX: LTR)	$1.87	3.60%
Pro Medicus Ltd (ASX: PME)	$61.84	3.24%
Domino’s Pizza Enterprises Ltd (ASX: DMP)	$125.61	3.12%

Our top 10 ASX shares today countdown is a recurring end-of-day summary to ensure you know which companies were making big moves on the day. Check-in at Fool.com.au after the market has closed during weekdays to see which stocks make the countdown.

The post Here are the top 10 ASX shares today appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are topping the volume charts this Thursday
• Here’s why the Nickel Mines (ASX:NIC) share price is soaring 15% so far this week
• Why is the Novonix (ASX:NVX) share price surging 11% to an all-time high today?
• ASX 200 (ASX:XJO) midday update: EML rockets, NAB given ACCC green light
• 5 things to watch on the ASX 200 on Thursday

Motley Fool contributor Mitchell Lawler owns shares of AFTERPAY T FPO and Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO and Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO and Pro Medicus Ltd. The Motley Fool Australia has recommended Dominos Pizza Enterprises Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3FOTkgj